Skip to main content
Top
Published in: Tumor Biology 8/2016

01-08-2016 | Original Article

MAP4K4 promotes epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma

Authors: Xiao-Jun Feng, Qing Pan, Shou-Mei Wang, Yun-cui Pan, Qian Wang, Huan-Huan Zhang, Ming-Hua Zhu, Shu-Hui Zhang

Published in: Tumor Biology | Issue 8/2016

Login to get access

Abstract

Our previous study has reported that mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) regulates the growth and survival of hepatocellular carcinoma (HCC) cells. This study was undertaken to explore the roles of MAP4K4 in the epithelial-mesenchymal transition (EMT) and metastasis in HCC. Effects of overexpression and knockdown of MAP4K4 on the migration, invasion, and EMT of HCC cells were examined. The in vivo role of MAP4K4 in lung metastasis of HCC was determined in nude mice. The relationship between MAP4K4 expression and EMT in human HCC specimens was determined by immunohistochemistry. MAP4K4 overexpression significantly enhanced the migration and invasion of MHCC-97L HCC cells, whereas MAP4K4 silencing hindered the migration and invasion of MHCC-97H HCC cells. MAP4K4-overexpressing cells undergo EMT, which was accompanied by downregulation of E-cadherin and upregulation of vimentin. In contrast, MAP4K4 silencing caused a reversion from a spindle morphology to cobblestone-like morphology and induction of E-cadherin and reduction of vimentin. Pretreatment with chemical inhibitors of JNK and NF-κB abolished MAP4K4-mediated migration, invasion, and regulation of EMT markers in MHCC-97L cells. Ectopic expression of MAP4K4 promoted and knockdown of MAP4K4 inhibited lung metastasis of HCC, which was associated with regulation of JNK and NF-κB signaling and EMT markers. High MAP4K4 immunoreactivity was inversely correlated with E-cadherin and was positively correlated with vimentin, phospho-JNK, and phospho-NF-κB in HCC specimens. Taken together, MAP4K4 promotes the EMT and invasiveness of HCC cells largely via activation of JNK and NF-κB signaling.
Appendix
Available only for authorised users
Literature
1.
go back to reference Boyle P, Levin B. World cancer report 2008. Avenue, Geneva, Switzerland: WHO Press; 2009. p. 350. Boyle P, Levin B. World cancer report 2008. Avenue, Geneva, Switzerland: WHO Press; 2009. p. 350.
2.
go back to reference Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 2010;15 Suppl 4:5–13.CrossRefPubMed Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 2010;15 Suppl 4:5–13.CrossRefPubMed
4.
go back to reference Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871–90.CrossRefPubMed Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871–90.CrossRefPubMed
5.
go back to reference Theys J, Jutten B, Habets R, Paesmans K, Groot AJ, Lambin P, et al. E-cadherin loss associated with EMT promotes radioresistance in human tumor cells. Radiother Oncol. 2011;99:392–7.CrossRefPubMedPubMedCentral Theys J, Jutten B, Habets R, Paesmans K, Groot AJ, Lambin P, et al. E-cadherin loss associated with EMT promotes radioresistance in human tumor cells. Radiother Oncol. 2011;99:392–7.CrossRefPubMedPubMedCentral
6.
go back to reference Smith BN, Bhowmick NA. Role of EMT in metastasis and therapy resistance. J Clin Med 2016; pii: E17 Smith BN, Bhowmick NA. Role of EMT in metastasis and therapy resistance. J Clin Med 2016; pii: E17
7.
go back to reference Dong Q, Zhu X, Dai C, Zhang X, Gao X, Wei J, et al. Osteopontin promotes epithelial-mesenchymal transition of hepatocellular carcinoma through regulating vimentin. Oncotarget. 2016. doi: 10.18632/oncotarget.7016. Dong Q, Zhu X, Dai C, Zhang X, Gao X, Wei J, et al. Osteopontin promotes epithelial-mesenchymal transition of hepatocellular carcinoma through regulating vimentin. Oncotarget. 2016. doi: 10.18632/oncotarget.7016.
8.
go back to reference Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148:349–61.CrossRefPubMedPubMedCentral Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148:349–61.CrossRefPubMedPubMedCentral
9.
go back to reference Dai W, Wang F, He L, Lin C, Wu S, Chen P, et al. Genistein inhibits hepatocellular carcinoma cell migration by reversing the epithelial-mesenchymal transition: partial mediation by the transcription factor nfat1. Mol Carcinog. 2015;54:301–11.CrossRefPubMed Dai W, Wang F, He L, Lin C, Wu S, Chen P, et al. Genistein inhibits hepatocellular carcinoma cell migration by reversing the epithelial-mesenchymal transition: partial mediation by the transcription factor nfat1. Mol Carcinog. 2015;54:301–11.CrossRefPubMed
10.
go back to reference Davis FM, Stewart TA, Thompson EW, Monteith GR. Targeting EMT in cancer: opportunities for pharmacological intervention. Trends Pharmacol Sci. 2014;35:479–88.CrossRefPubMed Davis FM, Stewart TA, Thompson EW, Monteith GR. Targeting EMT in cancer: opportunities for pharmacological intervention. Trends Pharmacol Sci. 2014;35:479–88.CrossRefPubMed
11.
go back to reference Vitorino P, Yeung S, Crow A, Bakke J, Smyczek T, West K, et al. Map4k4 regulates integrin-ferm binding to control endothelial cell motility. Nature. 2015;519:425–30.CrossRefPubMed Vitorino P, Yeung S, Crow A, Bakke J, Smyczek T, West K, et al. Map4k4 regulates integrin-ferm binding to control endothelial cell motility. Nature. 2015;519:425–30.CrossRefPubMed
13.
go back to reference Collins CS, Hong J, Sapinoso L, Zhou Y, Liu Z, Micklash K, et al. A small interfering RNA screen for modulators of tumor cell motility identifies map4k4 as a promigratory kinase. Proc Natl Acad Sci U S A. 2006;103:3775–80.CrossRefPubMedPubMedCentral Collins CS, Hong J, Sapinoso L, Zhou Y, Liu Z, Micklash K, et al. A small interfering RNA screen for modulators of tumor cell motility identifies map4k4 as a promigratory kinase. Proc Natl Acad Sci U S A. 2006;103:3775–80.CrossRefPubMedPubMedCentral
14.
go back to reference Liu AW, Cai J, Zhao XL, Jiang TH, He TF, Fu HQ, et al. Shrna-targeted map4k4 inhibits hepatocellular carcinoma growth. Clin Cancer Res. 2011;17:710–20.CrossRefPubMed Liu AW, Cai J, Zhao XL, Jiang TH, He TF, Fu HQ, et al. Shrna-targeted map4k4 inhibits hepatocellular carcinoma growth. Clin Cancer Res. 2011;17:710–20.CrossRefPubMed
15.
go back to reference Liang JJ, Wang H, Rashid A, Tan TH, Hwang RF, Hamilton SR, et al. Expression of map4k4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. Clin Cancer Res. 2008;14:7043–9.CrossRefPubMed Liang JJ, Wang H, Rashid A, Tan TH, Hwang RF, Hamilton SR, et al. Expression of map4k4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. Clin Cancer Res. 2008;14:7043–9.CrossRefPubMed
16.
go back to reference Zhao G, Wang B, Liu Y, Zhang JG, Deng SC, Qin Q, et al. Mirna-141, downregulated in pancreatic cancer, inhibits cell proliferation and invasion by directly targeting map4k4. Mol Cancer Ther. 2013;12:2569–80.CrossRefPubMed Zhao G, Wang B, Liu Y, Zhang JG, Deng SC, Qin Q, et al. Mirna-141, downregulated in pancreatic cancer, inhibits cell proliferation and invasion by directly targeting map4k4. Mol Cancer Ther. 2013;12:2569–80.CrossRefPubMed
17.
go back to reference Toiyama Y, Yasuda H, Saigusa S, Tanaka K, Inoue Y, Goel A, et al. Increased expression of slug and vimentin as novel predictive biomarkers for lymph node metastasis and poor prognosis in colorectal cancer. Carcinogenesis. 2013;34:2548–57.CrossRefPubMed Toiyama Y, Yasuda H, Saigusa S, Tanaka K, Inoue Y, Goel A, et al. Increased expression of slug and vimentin as novel predictive biomarkers for lymph node metastasis and poor prognosis in colorectal cancer. Carcinogenesis. 2013;34:2548–57.CrossRefPubMed
18.
go back to reference Schneider MR, Hiltwein F, Grill J, Blum H, Krebs S, Klanner A, et al. Evidence for a role of E-cadherin in suppressing liver carcinogenesis in mice and men. Carcinogenesis. 2014;35:1855–62.CrossRefPubMed Schneider MR, Hiltwein F, Grill J, Blum H, Krebs S, Klanner A, et al. Evidence for a role of E-cadherin in suppressing liver carcinogenesis in mice and men. Carcinogenesis. 2014;35:1855–62.CrossRefPubMed
19.
go back to reference Qiu MH, Qian YM, Zhao XL, Wang SM, Feng XJ, Chen XF, et al. Expression and prognostic significance of map4k4 in lung adenocarcinoma. Pathol Res Pract. 2012;208:541–8.CrossRefPubMed Qiu MH, Qian YM, Zhao XL, Wang SM, Feng XJ, Chen XF, et al. Expression and prognostic significance of map4k4 in lung adenocarcinoma. Pathol Res Pract. 2012;208:541–8.CrossRefPubMed
20.
go back to reference Zohn IE, Li Y, Skolnik EY, Anderson KV, Han J, Niswander L. P38 and a p38-interacting protein are critical for downregulation of E-cadherin during mouse gastrulation. Cell. 2006;125:957–69.CrossRefPubMed Zohn IE, Li Y, Skolnik EY, Anderson KV, Han J, Niswander L. P38 and a p38-interacting protein are critical for downregulation of E-cadherin during mouse gastrulation. Cell. 2006;125:957–69.CrossRefPubMed
21.
go back to reference Song FN, Duan M, Liu LZ, Wang ZC, Shi JY, Yang LX, et al. Rankl promotes migration and invasion of hepatocellular carcinoma cells via NF-kappab-mediated epithelial-mesenchymal transition. PLoS One. 2014;9, e108507.CrossRefPubMedPubMedCentral Song FN, Duan M, Liu LZ, Wang ZC, Shi JY, Yang LX, et al. Rankl promotes migration and invasion of hepatocellular carcinoma cells via NF-kappab-mediated epithelial-mesenchymal transition. PLoS One. 2014;9, e108507.CrossRefPubMedPubMedCentral
22.
go back to reference Song R, Song H, Liang Y, Yin D, Zhang H, Zheng T, et al. Reciprocal activation between ATPase inhibitory factor 1 and NF-kappab drives hepatocellular carcinoma angiogenesis and metastasis. Hepatology. 2014;60:1659–73.CrossRefPubMed Song R, Song H, Liang Y, Yin D, Zhang H, Zheng T, et al. Reciprocal activation between ATPase inhibitory factor 1 and NF-kappab drives hepatocellular carcinoma angiogenesis and metastasis. Hepatology. 2014;60:1659–73.CrossRefPubMed
23.
go back to reference Ching YP, Leong VY, Lee MF, Xu HT, Jin DY, Ng IO. P21-activated protein kinase is overexpressed in hepatocellular carcinoma and enhances cancer metastasis involving c-Jun NH2-terminal kinase activation and paxillin phosphorylation. Cancer Res. 2007;67:3601–8.CrossRefPubMed Ching YP, Leong VY, Lee MF, Xu HT, Jin DY, Ng IO. P21-activated protein kinase is overexpressed in hepatocellular carcinoma and enhances cancer metastasis involving c-Jun NH2-terminal kinase activation and paxillin phosphorylation. Cancer Res. 2007;67:3601–8.CrossRefPubMed
24.
go back to reference Tsai JP, Hsiao PC, Yang SF, Hsieh SC, Bau DT, Ling CL, et al. Licochalcone a suppresses migration and invasion of human hepatocellular carcinoma cells through downregulation of mkk4/JNK via NF-kappab mediated urokinase plasminogen activator expression. PLoS One. 2014;9, e86537.CrossRefPubMedPubMedCentral Tsai JP, Hsiao PC, Yang SF, Hsieh SC, Bau DT, Ling CL, et al. Licochalcone a suppresses migration and invasion of human hepatocellular carcinoma cells through downregulation of mkk4/JNK via NF-kappab mediated urokinase plasminogen activator expression. PLoS One. 2014;9, e86537.CrossRefPubMedPubMedCentral
25.
go back to reference Zhu XL, Wang YL, Chen JP, Duan LL, Cong PF, Qu YC, et al. Alternol inhibits migration and invasion of human hepatocellular carcinoma cells by targeting epithelial-to-mesenchymal transition. Tumour Biol. 2014;35:1627–35.CrossRefPubMed Zhu XL, Wang YL, Chen JP, Duan LL, Cong PF, Qu YC, et al. Alternol inhibits migration and invasion of human hepatocellular carcinoma cells by targeting epithelial-to-mesenchymal transition. Tumour Biol. 2014;35:1627–35.CrossRefPubMed
Metadata
Title
MAP4K4 promotes epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma
Authors
Xiao-Jun Feng
Qing Pan
Shou-Mei Wang
Yun-cui Pan
Qian Wang
Huan-Huan Zhang
Ming-Hua Zhu
Shu-Hui Zhang
Publication date
01-08-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 8/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5022-1

Other articles of this Issue 8/2016

Tumor Biology 8/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine